NKT细胞的生物特性及其在多发性骨髓瘤中应用的研究进展

摘要: NKT细胞是一种特殊的T淋巴细胞亚群，其表面既有T细胞受体，又有NK细胞受体。NKT细胞在肿瘤、自身免疫性疾病和微生物感染中起到调节免疫应答的作用，是联系固有免疫和获得性免疫的“桥梁”之一。多发性骨髓瘤（multiple myeloma，MM）是一种浆细胞异常增殖的恶性血液系统疾病。MM细胞表达CD1d分子并且可被具有CD1d限制性的NKT细胞杀伤。近些年，NKT细胞的抗MM作用成为研究热点，本文就NKT细胞生物特性及其在MM治疗中的应用进行综述。
- NKT细胞 /
- 多发性骨髓瘤 /
- 应用 /
- 治疗
Abstract: Natural killer T (NKT) cells constitute a distinct subpopulation of T cells that express T-cell receptors and NKT cell markers. NKT cells are one of the bridges that link the innate and adaptive immune systems and play a vital role in regulating immune responses in tumors, autoimmune diseases, and microbial infection. Multiple myeloma is a hematologic malignancy due to the uncontrolled proliferation of plasma cells. Multiple myeloma cells express CD1d and are sensitive to lysis by CD1d-restricted natural killer T cells. In recent years, the antitumor effects of NKT cells in multiple myeloma have become a hot research topic. Here, we reviewed the biological characteristics of NKT cells and their applications in multiple myeloma.
- natural killer T (NKT) cells /
- multiple myeloma /
- application /
- therapy

HTML全文

参考文献(31)

[1]	Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family[J]. Nat Immunol, 2010, 11(3):197-206. doi: 10.1038/ni.1841
[2]	Patel O, Pellicci DG, Gras S, et al. Recognition of CD1d-sulfatide mediated by a typeⅡnatural killer T cell antigen receptor[J]. Nat Immunol, 2012, 13(9):857-863. doi: 10.1038/ni.2372
[3]	Marrero I, Ware R, Kumar V. TypeⅡNKT cells in inflammation, autoimmunity, microbial immunity, and cancer[J]. Front Immunol, 2015, (6):316. http://europepmc.org/articles/PMC4470258/
[4]	Nair S, Boddupalli CS, Verma R, et al. TypeⅡNKT-TFH cells against gaucher lipids regulate B- cell immunity and inflammation[J]. Blood, 2015, 125(8):1256-1271. doi: 10.1182/blood-2014-09-600270
[5]	Girardi E, Maricic I, Wang J, et al. TypeⅡnatural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens[J]. Nat Immunol, 2012, 13(9):851-856. doi: 10.1038/ni.2371
[6]	Kumar V, Delovitch TL. Different subsets of natural killer T cells may vary in their roles in health and disease[J]. Immunol, 2014, 142 (3):321-336. doi: 10.1111/imm.2014.142.issue-3
[7]	Favreau M, Vanderkerken K, Elewaut D, et al. Does an NKT- cellbased immunotherapeutic approach have a future in multiple myeloma[J]? Oncotarget, 2016, 7(17):23128-23140. http://europepmc.org/articles/PMC5029615/
[8]	Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity[J]. Front Immunol, 2014, (5):543. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004604295
[9]	Fallarini S, Paoletti T, Orsi BN, et al. Invariant NKT cells increase drug-induced osteosarcoma cell death[J]. Br J Pharmacol, 2012, 167 (7):1533-1549. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0229745217/
[10]	Macho-Fernandez E, Brigl M. The extended family of CD1d-restricted NKT cells: sifting through a mixed bag of TCRs, antigens, and functions[J]. Front Immunol, 2015, (6):362. http://europepmc.org/articles/PMC4517383
[11]	Zajonc DM, Girardi E. Recognition of microbial glycolipids by natural killer T cells[J]. Front Immunol, 2015, (6):400. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523824/
[12]	Robertson FC, Berzofsky JA, Terabe M. NKT cell networks in the regulation of tumor immunity[J]. Frontiers in Immunol, 2014, (5):543. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004604295
[13]	Masaki T, So M, Jong-Myun P, et al. Transforming growth factor-b production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence[J]. J Exp Med, 2003, 198(11):1741-1752. doi: 10.1084/jem.20022227
[14]	Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL- 13 and the IL- 4RSTAT6 pathway[J]. 2000, 1(6): 515-520.
[15]	Renukaradhya GJ, Khan MA, Vieira M, et al. TypeⅠNKT cells protect (and typeⅡNKT cells suppress) the host's innate antitumor immune response to a B- cell lymphoma[J]. Blood, 2008, 111(12): 5637-5645. doi: 10.1182/blood-2007-05-092866
[16]	Ambrosino E, Terabe M, Halder RC, et al. Cross-regulation between typeⅠand typeⅡNKT cells in regulating tumor immunity: a new immunoregulatory axis[J]. J Immunol, 2007, 179(8):5126-5136. doi: 10.4049/jimmunol.179.8.5126
[17]	Terabe M, Berzofsky JA. The immunoregulatory role of typeⅠand typeⅡNKT cells in cancer and other diseases[J]. Cancer Immunol Immunother, 2014, 63(3):199-213. doi: 10.1007/s00262-013-1509-4
[18]	Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma[J]. Int J Hematol, 2018, 107(3):278-285. doi: 10.1007/s12185-018-2405-7
[19]	Chan AC, Neeson P, Leeansyah E, et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy[J]. Clin Exp Immunol, 2014, 175(1):49-58. doi: 10.1111/cei.2014.175.issue-1
[20]	Richter J, Neparidze N, Zhang L, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma[J]. Blood, 2013, 121(3):423-430. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=JJ0228493644
[21]	Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma[J]. J Exp Med, 2003, 197 (12):1667-1676. doi: 10.1084-jem.20021650/
[22]	Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges[J]. Clin Immunol, 2011, 140(2):160-166. doi: 10.1016/j.clim.2010.12.010
[23]	Spanoudakis E, Hu M, Naresh K, et al. Regulation of multiple myeloma survival and progression by CD1d[J]. Blood, 2009, 113(11): 2498-2507. doi: 10.1182/blood-2008-06-161281
[24]	Hayakawa Y, Takeda K, Yagita H, et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide[J]. Blood, 2002, 100(5):1728-1733. http://europepmc.org/abstract/med/12176894
[25]	Favreau M, Menu E, Gaublomme D, et al. Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma[J]. Leukemia, 2017, 31(12):2678-2685. doi: 10.1038/leu.2017.146
[26]	Jiang F, Liu H, Liu Z, et al. Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease[J]. J Cell Mol Med, 2018, 22(5):2706-2716. doi: 10.1111/jcmm.2018.22.issue-5
[27]	Spanoudakis E, Papoutselis M, Terpos E, et al. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma[J]. Blood Cancer J, 2016, 6(11):e500. doi: 10.1038/bcj.2016.108
[28]	Hu M, Bassett JH, Danks L, et al. Activated invariant NKT cells regulate osteoclast development and function[J]. J Immunol, 2011, 186 (5):2910-2917. doi: 10.4049/jimmunol.1002353
[29]	Chang DH, Deng H, Matthews P, et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer[J]. Blood, 2008, 112(4):1308-1316. doi: 10.1182/blood-2008-04-149831
[30]	Mattarollo SR, West AC, Steegh K, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma[J]. Blood, 2012, 120(15):3019-3029. doi: 10.1182/blood-2012-04-426643
[31]	Hong S, Lee H, Jung K, et al. Tumor cells loaded with alpha-galactosylceramide promote therapeutic NKT- dependent anti- tumor immunity in multiple myeloma[J]. Immunol Lett, 2013, 156(1-2):132-139. doi: 10.1016/j.imlet.2013.10.002